FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

FDA approves perampanel as adjunctive treatment for partial-onset seizures in patients with epilepsy aged 12 years and older

Newsletter